SWSabrina De Winter

Sabrina De Winter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sabrina De Winter has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Uncovering Medication Errors Leading to Hospital Admissions in the Emergency Department: An External, Prospective Validation of Clinical Decision Rules

    by Nadjia Amini, Sabrina De Winter, Sanne Nijs, Ann‐Sophie Jacob, Sandra Verelst, Peter Vanbrabant, Lorenz Van der Linden, Isabel Spriet

    Purpose: Drug‐related admissions (DRAs) remain highly prevalent and are linked with increased morbidity and mortality. Rapid and accurate identification is key to both their acute management and secondary prevention. To this end, two clinical decision rules (CDRs) were recently developed to identify the causal adverse drug event (ADE‐CDR) or the underlying adverse drug reaction (ADR‐CDR). The aim of this study was to assess the diagnostic accuracy of both CDRs in a new patient cohort. Methods: A prospective, cross‐sectional study was conducted at the emergency department (ED) of the University Hospitals Leuven in Belgium. Adult patients were included if admitted to the hospital via the ED. DRA was adjudicated by team consensus and compared to both ADE‐CDR and ADR‐CDR. Diagnostic accuracy was determined, and multivariable logistic regression was used to explore risk factors for DRAs. Results: From 1 October 2018 to 26 September 2019, 438 patients were included, 58 (13.2%) of whom incurred a DRA. ADE‐CDR had a sensitivity of 89.7% and a specificity of 22.4%. The sensitivity and specificity of ADR‐CDR were 46.6% and 60.8%, respectively. Two risk factors were found for DRA: the presence of ≥ 1 comorbidity (odds ratio (OR) 4.71, 95% confidence interval (CI): 1.42–15.49) and ambulance transport (OR 2.16, 95% CI: 1.21–3.82). Conclusion: ADE‐CDR showed a high sensitivity. In terms of specificity, both CDRs were unable to rule in DRAs in our setting. Conversely, the ADE‐CDR showcased the potential to rule out DRAs.


  • Open Access

    A Prediction Model to Identify Clinically Relevant Medication Discrepancies at the Emergency Department (MED-REC Predictor): Development and Validation Study

    by Greet Van De Sijpe, Matthias Gijsen, Lorenz Van der Linden, Stephanie Strouven, Eline Simons, Emily Martens, Nele Persan, Veerle Grootaert, Veerle Foulon, Minne Casteels, et al.

    Background: Many patients do not receive a comprehensive medication reconciliation, mostly owing to limited resources. We hence need an approach to identify those patients at the emergency department (ED) who are at increased risk for clinically relevant discrepancies. Objective: The aim of our study was to develop and externally validate a prediction model to identify patients at risk for at least 1 clinically relevant medication discrepancy upon ED presentation. Methods: A prospective, multicenter, observational study was conducted at the University Hospitals Leuven and General Hospital Sint-Jan Brugge-Oostende AV, Belgium. Medication histories were obtained from patients admitted to the ED between November 2017 and May 2022, and clinically relevant medication discrepancies were identified. Three distinct datasets were created for model development, temporal external validation, and geographic external validation. Multivariable logistic regression with backward stepwise selection was used to select the final model. The presence of at least 1 clinically relevant discrepancy was the dependent variable. The model was evaluated by measuring calibration, discrimination, classification, and net benefit. Results: We included 824, 350, and 119 patients in the development, temporal validation, and geographic validation dataset, respectively. The final model contained 8 predictors, for example, age, residence before admission, number of drugs, and number of drugs of certain drug classes based on Anatomical Therapeutic Chemical coding. Temporal validation showed excellent calibration with a slope of 1.09 and an intercept of 0.18. Discrimination was moderate with a c-index (concordance index) of 0.67 (95% CI 0.61-0.73). In the geographic validation dataset, the calibration slope and intercept were 1.35 and 0.83, respectively, and the c-index was 0.68 (95% CI 0.58-0.78). The model showed net benefit over a range of clinically reasonable threshold probabilities and outperformed other selection criteria. Conclusions: Our software-implemented prediction model shows moderate performance, outperforming random or typical selection criteria for medication reconciliation. Depending on available resources, the probability threshold can be customized to increase either the specificity or the sensitivity of the model.


  • Open Access

    A Prediction Model to Identify Clinically Relevant Medication Discrepancies at the Emergency Department (MED-REC Predictor): Development and Validation Study (Preprint)

    by Greet Van De Sijpe, Matthias Gijsen, Lorenz Van der Linden, Stephanie Strouven, Eline Simons, Emily Martens, Nele Persan, Veerle Grootaert, Veerle Foulon, Minne Casteels, et al.

    BACKGROUND Many patients do not receive a comprehensive medication reconciliation, mostly owing to limited resources. We hence need an approach to identify those patients at the emergency department (ED) who are at increased risk for clinically relevant discrepancies. OBJECTIVE The aim of our study was to develop and externally validate a prediction model to identify patients at risk for at least 1 clinically relevant medication discrepancy upon ED presentation. METHODS A prospective, multicenter, observational study was conducted at the University Hospitals Leuven and General Hospital Sint-Jan Brugge-Oostende AV, Belgium. Medication histories were obtained from patients admitted to the ED between November 2017 and May 2022, and clinically relevant medication discrepancies were identified. Three distinct datasets were created for model development, temporal external validation, and geographic external validation. Multivariable logistic regression with backward stepwise selection was used to select the final model. The presence of at least 1 clinically relevant discrepancy was the dependent variable. The model was evaluated by measuring calibration, discrimination, classification, and net benefit. RESULTS We included 824, 350, and 119 patients in the development, temporal validation, and geographic validation dataset, respectively. The final model contained 8 predictors, for example, age, residence before admission, number of drugs, and number of drugs of certain drug classes based on Anatomical Therapeutic Chemical coding. Temporal validation showed excellent calibration with a slope of 1.09 and an intercept of 0.18. Discrimination was moderate with a c-index (concordance index) of 0.67 (95% CI 0.61-0.73). In the geographic validation dataset, the calibration slope and intercept were 1.35 and 0.83, respectively, and the c-index was 0.68 (95% CI 0.58-0.78). The model showed net benefit over a range of clinically reasonable threshold probabilities and outperformed other selection criteria. CONCLUSIONS Our software-implemented prediction model shows moderate performance, outperforming random or typical selection criteria for medication reconciliation. Depending on available resources, the probability threshold can be customized to increase either the specificity or the sensitivity of the model.

  • Open Access

    4CPS-114 Development and prospective validation of a prediction model to identify clinically relevant medication discrepancies at the emergency department

    by G Van De Sijpe, M Gijsen, L Van Der Linden, S Strouven, V Foulon, M Casteels, S Verelst, P Vanbrabant, S De Winter, I Spriet

    Background and Importance Medication discrepancies occur in a majority of hospital admissions to the emergency department (ED) and are a major source of avoidable harm. Obtaining an accurate medication history is essential to identify drug-related problems early on. However, the medication reconciliation process is prone to many errors and is furthermore labour-intensive. As a result, many patients simply do not receive a complete medication reconciliation, mostly owing to limited recourses. We hence need an approach which enables us to identify those patients at the ED who are at increased risk for clinically relevant discrepancies. Aim and Objectives To develop and prospectively validate a prediction model to identify patients who are at risk for at least one clinically relevant medication discrepancy at the time of ED presentation. Material and Methods A prospective study was carried out at the ED. Medication histories were obtained and clinically relevant discrepancies were identified, using an internally validated scoring tool. Two distinct datasets were created. A first dataset (n=824) was used to build and internally validate a prediction model. We used multivariable logistic regression with backward stepwise selection to select the final model. A second dataset (n= 350) was used to prospectively validate the prediction model. The predictive performance of this model was assessed by measuring calibration, discrimination and classification. Results The final model contained nine predictors that can easily be obtained upon ED admission, including age, origin before admission (home/nursing home) and number of drugs. Prospective validation showed excellent calibration with a slope of 1.09 and an intercept of 0.18. Discrimination was moderate with a c-index of 0.66. Using a probability threshold of 0.4, the sensitivity, specificity, positive predictive value, negative predictive value and alert rate was 41%, 81%, 56%, 70% and 27%, respectively. Conclusion and Relevance The presence of at least one clinically relevant medication discrepancy can be predicted by our model with moderate performance. Using our prediction model is more efficient than performing medication reconciliation at random and can guide the rational use of limited resources at the ED. Depending on the available resources, different probability thresholds can be applied to increase either the specificity or the sensitivity of the prediction model. Conflict of Interest No conflict of interest

  • Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis

    by Sabrina De Winter, Reinier van Hest, Erwin Dreesen, Pieter Annaert, Joost Wauters, Wouter Meersseman, Nele Van Den Eede, Stefanie Desmet, Sandra Verelst, Peter Vanbrabant, et al.

    Background There may be a difference between the determinants of amikacin exposure in emergency department (ED) versus intensive care (ICU) patients, and the peak amikacin concentration varies widely between patients. Moreover, when the first dose of antimicrobials is administered to septic patients admitted to the ED, fluid resuscitation and vasopressors have just been initiated. Nevertheless, population pharmacokinetic modelling data for amikacin in ED patients are unavailable. Objective The aim of this study was to quantify the interindividual variability (IIV) in the pharmacokinetics of amikacin in patients admitted to the ED and to identify the patient characteristics that explain this IIV. Methods Patients presenting at the ED with severe sepsis or septic shock were randomly assigned to receive amikacin 25 mg/kg or 15 mg/kg intravenously. Blood samples were collected at 1, 6 and 24 h after the onset of the first amikacin infusion. Data were analysed using nonlinear mixed-effects modelling. Results A two-compartment population pharmacokinetic model was developed based on 279 amikacin concentrations from 97 patients. The IIV in clearance (CL) and central distribution volume (V1) were 71% and 26%, respectively. Body mass index (BMI), serum total protein level, serum sodium level, and fluid balance 24 h after amikacin administration explained 30% of the IIV in V1, leaving 18% of the IIV unexplained. BMI and creatinine clearance according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 24 h after amikacin administration explained 46% of the IIV in CL, and 39% remained unexplained. Conclusion The IIV of amikacin pharmacokinetics in ED patients is large. Higher doses may be considered in patients with low serum sodium levels, low total protein levels, or a high fluid balance. Trial Registration ClinicalTrials.gov ID: NCT02365272.


  • Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial

    by Sabrina De Winter, Joost Wauters, Wouter Meersseman, Jan Verhaegen, Eric Van Wijngaerden, Willy Peetermans, Pieter Annaert, Sandra Verelst, Isabel Spriet


  • Stability of Drugs Used in Helicopter Air Medical Emergency Services: An Exploratory Study

    by Sabrina De Winter, Koen Bronselaer, Peter Vanbrabant, Bart Blanchaert, Marwa F. Mansour, Daniele Brandolisio, Stijn De Jonge, Peter Slaets, Paul Sas, Ann Van Schepdael, et al.


  • Exploring the relationship between fall risk-increasing drugs and fall-related fractures

    by Sabrina De Winter, Sarah Vanwynsberghe, Veerle Foulon, Eddy Dejaeger, Johan Flamaing, An Sermon, Lorenz Van der Linden, Isabel Spriet

    Hospital admissions due to fall-related fractures are a major problem in the aging population. Several risk factors have been identified, including drug use. Most studies often retrieved prescription-only drugs from national databases. These are associated with some limitations as they do not always reliably reproduce the complete patient’s active drug list. To evaluate the association between the number of FRIDs intake identified by a standardised medication reconciliation process and a fall-related fracture leading to a hospital admission in older adults. The first cohort has been recruited from one traumatology ward of a tertiary teaching hospital in Belgium and the second cohort has been recruited from 11 community pharmacies in Belgium. A prospective study with two individually matched cohorts was performed. Adult patients (≥75 years) admitted with an injury due to a fall were included in the first cohort (faller group). The second cohort consisted of patients who did not suffer from a fall within the last 6 months (non-faller group). Matching was performed for age, gender, place of residence and use of a walking aid. In both groups, clinical pharmacists and undergraduate pharmacy students obtained the medication history, using a standardised approach. A list of drugs considered to increase the risk of falling was created. It included cardiovascular drugs and drugs acting on the nervous system. A linear mixed model was used to compare the number of fall risk-increasing drugs between fallers and non-fallers. The number of fall risk-increasing drugs in a faller versus a non-faller group. Sixty-one patients were matched with 121 non-fallers. Patients received on average 3.1 ± 2.1 and 3.2 ± 1.8 fall risk-increasing drugs in the faller and in the non-faller group, respectively. The mean number of fall risk-increasing drugs was comparable in both groups (p = 0.844), even after adjusting for alcohol consumption, fear of falling, vision and foot problems (p = 0.721). In a sample of hospitalised patients admitted for a fall-related injury, no significant difference in the number of fall risk-increasing drugs versus that of an outpatient group of non-fallers was found.


  • Pharmacokinetic changes after placement of a transjugular intrahepatic portosystemic shunt

    by Sabrina De Winter, Sandra Verelst, Joost Wauters, Lorenz Van der Linden, Chris Verslype, Ludo Willems, Isabel Spriet


  • Impact of Temperature Exposure on Stability of Drugs in a Real-World Out-of-Hospital Setting

    by Sabrina De Winter, Peter Vanbrabant, N.T. Tuong Vi, Xiaolan Deng, Isabel Spriet, Ann Van Schepdael, Jean-Bernard Gillet